Cancer News and Research

Latest Cancer News and Research

Patients are not presented with information about prostate cancer treatment options: Urologists

At the recent meeting of the American Urological Association in San Francisco, researchers presented studies regarding the decision making process men go through when considering proposed prostate cancer treatments. Dr. Vorstman, renowned Florida urologist, believes these studies would have more meaning if patients were presented with information about prostate cancer treatment options in a different fashion.

7 Jul 2010

Study identifies factors that control production of HSCs

A team of researchers from the Institute for Research in Immunology and Cancer of the University of Montreal have made significant progress in the understanding of blood-producing (hematopoietic) stem cells. The study led by IRIC Chief Executive Officer and Scientific Director, Dr. Guy Sauvageau, identifies factors that control the production of hematopoietic stem cells.

7 Jul 2010

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's lead oncology compound, exhibits superior activity compared to irinotecan as part of either a monotherapy or combination regimen in tumor models of gastrointestinal cancers.

7 Jul 2010

TGen develops G-SQZ technique for genomic data processing

A new computer data compression technique called Genomic SQueeZ, developed by the Translational Genomics Research Institute, will allow genetic researchers and others to store, analyze and share massive volumes of data in less space and at lower cost.

7 Jul 2010

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

7 Jul 2010

TWINCORE researchers develop new model approaches for HCV research

The hepatitis C virus is highly specialised. We humans are its natural hosts. The only other living organisms that could be infected with the hepatitis C virus in the lab are chimpanzees. Nevertheless it is - from the viewpoint of the virus - highly successful: around 170 million people are chronically infected with the virus. And with the chronic infection the risk of developing liver cancer also increases.

7 Jul 2010

New Center for Image-Guided Intervention opened at MSKCC

Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC's new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.

7 Jul 2010

Extended treatment with blood thinner benefits patients immobilized by acute medical illness: Study

A treatment plan used to prevent potentially dangerous blood clots in recovering surgical patients can also benefit some patients immobilized by acute medical illness, doctors have found in a multi-institutional study.

7 Jul 2010

New research shows cellular changes in fat tissue lead to type 2 diabetes

Cellular changes in fat tissue-not the immune system-lead to the "hyperinflammation" characteristic of obesity-related glucose intolerance and type 2 diabetes, according to new research from the University of Cincinnati.

7 Jul 2010

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies, Emory and Georgia Tech scientists have demonstrated.

7 Jul 2010

MicroRNAs accurately identify four histological types of renal tumors: Study

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that a peer-reviewed article entitled "Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression" has been published in the online version of The Journal of Molecular Diagnostics.

7 Jul 2010

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.

7 Jul 2010

Virginia Hospital Center selects CredenceHealth to provide best quality of care for patients

CredenceHealth, a provider of real-time clinical intelligence for hospitals and health plans, announced today that Virginia Hospital Center , a 342-bed not-for-profit hospital in Arlington, Virginia, has selected CredenceHealth for the hospital's latest patient quality improvement initiative.

7 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.

7 Jul 2010

Initial Phase II study results of ofatumumab in patients with RRMS announced

Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis.

7 Jul 2010

Study finds additional targets for new therapies to treat advanced prostate cancer patients

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

7 Jul 2010

VA addresses health concerns including possible HIV exposure and Veterans' general poor health

"The Democratic chairman of the House Veterans Affairs Committee lambasted the Obama administration over its handling of an incident at a St. Louis VA center in which more than 1,800 veterans were told they may have been exposed to HIV. ... The Department of Veterans Affairs last month sent a letter to 1,812 patients informing them that could have been exposed to HIV and other deadly viruses because of dental equipment that was insufficiently sterilized over a period of 13 months."

7 Jul 2010

Aspire Capital Fund to purchase Bionovo shares of common stock worth $15.0 million

Bionovo, Inc. (Nasdaq: BNVI) announced today that it has entered into a common stock purchase agreement with Aspire Capital Fund LLC, an Illinois limited liability company, which provides that, subject to certain conditions and limitations, Aspire Capital is committed to purchase up to an aggregate of $15.0 million of Bionovo shares of common stock over a two year term, based on prevailing market prices over a period preceding each sale.

7 Jul 2010

Hologic enters definitive agreement to acquire Sentinelle Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that it has entered into a definitive agreement to acquire Sentinelle Medical Inc., a leading provider of Magnetic Resonance Imaging (MRI) breast coils, tables and visualization software.

From Hologic, Inc. 7 Jul 2010

Cancer News and Research

Latest Cancer News and Research

Patients are not presented with information about prostate cancer treatment options: Urologists

Study identifies factors that control production of HSCs

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

TGen develops G-SQZ technique for genomic data processing

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

TWINCORE researchers develop new model approaches for HCV research

New Center for Image-Guided Intervention opened at MSKCC

Extended treatment with blood thinner benefits patients immobilized by acute medical illness: Study

New research shows cellular changes in fat tissue lead to type 2 diabetes

Multicolor quantum dots can distinguish Reed-Sternberg cells, article shows

MicroRNAs accurately identify four histological types of renal tumors: Study

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Virginia Hospital Center selects CredenceHealth to provide best quality of care for patients

QIAGEN receives CE conformity marking for careHPV Test

Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis

Initial Phase II study results of ofatumumab in patients with RRMS announced

Study finds additional targets for new therapies to treat advanced prostate cancer patients

VA addresses health concerns including possible HIV exposure and Veterans' general poor health

Aspire Capital Fund to purchase Bionovo shares of common stock worth $15.0 million

Hologic enters definitive agreement to acquire Sentinelle Medical

Cancer Research - Second Edition eBook

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in